SAN DIEGO--(BUSINESS WIRE)--Aug. 9, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced the pricing of an underwritten public offering of
6,060,606 shares of its common stock, offered at a price to the public
of $33.00 per share. The gross proceeds from this offering to ACADIA are
expected to be approximately $200.0 million, before deducting
underwriting discounts and commissions and other estimated offering
expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day
option to purchase up to an aggregate of 909,090 additional shares of
common stock. The offering is expected to close on August 15, 2016,
subject to customary closing conditions.
J.P. Morgan Securities LLC, Goldman, Sachs & Co. and BofA Merrill Lynch
are acting as the joint book-running managers for the offering. Cowen
and Company, LLC, Piper Jaffray & Co. and Needham & Company, LLC are
acting as co-managers for the offering.
The shares of common stock described above are being offered by ACADIA
pursuant to a shelf registration statement filed by ACADIA with the
Securities and Exchange Commission (SEC) that became automatically
effective on March 3, 2014. A preliminary prospectus supplement related
to the offering was filed with the SEC and is available on the SEC’s
website located at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus related to this offering, when available, may be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)
803-9204, or by email to: firstname.lastname@example.org,
or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West
Street, New York, NY 10282, or by telephone at (866) 471-2526, or by
email to: email@example.com,
or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd
floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by
email to: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders.
Statements in this press release that are not strictly historical in
nature, including statements related to the expected proceeds and timing
of the offering of common stock by ACADIA, are forward-looking
statements. These statements are only predictions based on current
information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
market risks and uncertainties and the satisfaction of customary closing
conditions for an offering of securities. For a discussion of these and
other factors, please refer to ACADIA’s annual report on Form 10-K for
the year ended December 31, 2015 as well as ACADIA’s subsequent filings
with the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160809006538/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Senior
Director, Investor Relations